Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of ...

Laboratory testing and clinical trial services giant LabCorp plans to spin off its drug development business as an independent, publicly traded company. It’s the latest in a string of corporate ...

Laboratory Corp of America Holdings missed estimates for quarterly profit on Tuesday, as its drug development unit struggled against curbs on animal imports, while a sharp fall in sales of COVID ...

LH announced that it is pursuing a tax-free spinoff of its Drug Development segment. Our downside case is roughly $230 to $240 assuming earnings remain in line with estimates.

Laboratory Corp of America Holdings cut its annual profit forecast on Thursday following the spin off of its clinical development business, Fortrea .

Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services.

LH, $257.94; Market Capitalization: $23.3 billion), a leading global life sciences company, announced that its Board of Directors authorized a plan to spin-off Clinical Development business into ...

Article ‘Count’ and ‘Share’ for Labcorp Drug Development based on listed parameters only. The articles listed below published by authors from Labcorp Drug Development, organized by journal ...

Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives.

As a leading independent diagnostic laboratory, LabCorp participates in a highly attractive duopoly that offers favorable prospects as healthcare moves toward reformed payment models, like the ...

Laboratory Corp of America Holdings said on Thursday it would spin off its wholly owned business focused on clinical drug trials, sending its shares up nearly 4%.